The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
New agreement means NL Hydro can buy power from Corner Brook Pulp and Paper at reduced rate
New CAO at Qalipu First Nation, Brad Evoy, was founding member at Bay of Islands Radio
MHA and former TV news reporter releases Christmas recording, second one this month
St. Anthony man charged with impaired after single vehicle crash near Wiltondale Friday night
